Literature DB >> 31749313

Real-time PCR based HLA-B*27 screening directly in whole blood.

Kathrin Geiger1, Christina Zach1,2, Andreas Leiherer1,2,3, Peter Fraunberger2, Heinz Drexel1,3,4,5, Axel Muendlein1.   

Abstract

The linkage between the occurrence of human leucocyte antigen B*27 (HLA-B*27) and ankylosing spondylitis or other related spondyloarthritides is well documented. PCR based methods are widely used for HLA-B*27 screening. To refine HLA-B*27 testing we aimed at establishing a real-time PCR protocol to detect the HLA-B*27 allele directly in blood samples, without DNA extraction. HLA-B*27 analysis was performed by two real-time PCRs using TaqMan primer-probe assays for B*27 specific amplification of exon 2 or exon 3 of the HLA-B gene together with a mutant of Taq polymerase for direct blood PCR. Conditions for direct blood PCR were optimized and the reliability of the direct blood PCR protocol was evaluated by re-genotyping over 200 blood samples from patients who previously underwent routine DNA-based HLA-B*27 testing. Heating blood samples at 95°C for 10 minutes significantly improved PCR performance. Results from real-time PCR based HLA-B*27 testing directly in blood of over 200 patients were in 100% concordance with results obtained by routine DNA-based HLA-B*27 genotyping. In summary, we present a reliable real-time PCR protocol for HLA-B*27 screening directly in whole blood supporting fast clarification of the presence of ankylosing spondylitis or other spondyloarthritides in suspected cases.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990HLA-B*27; ankylosing spondylitis; direct blood PCR; real-time PCR

Mesh:

Substances:

Year:  2019        PMID: 31749313     DOI: 10.1111/tan.13767

Source DB:  PubMed          Journal:  HLA        ISSN: 2059-2302            Impact factor:   4.513


  1 in total

1.  Whole blood samples for faster real-time PCR analysis of thrombophilic mutations in SARS-CoV-2 virus positive patients.

Authors:  M Beránek; V Koblížek; P Dulíček; J Hegerová; V Palička
Journal:  Physiol Res       Date:  2022-05-26       Impact factor: 2.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.